Medarex deal

MEDX (Princeton, N.J.) acquired a three-year option from Immuno-Designed Molecules (France) for the exclusive U.S. rights to macrophage activated killer cells (MAK), a cellular therapy that increases the therapeutic capacity of white blood cells.

MAK technology extracts and matures monocytes and treats them ex vivo with a cytokine that enhances their ability to react with disease cells. MEDX said the technology has potential applications in cancer therapy in conjuction with MEDX's Bispecific antibodies, in vaccine development, as a drug delivery system and in gene therapy applications. Immuno-Designed Molecules has conducted Phase I trials in several malignancies and is developing Phase II trials to be conducted in Europe. ...